$ALMS News

Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements

Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?

Chardan Capital Maintains Buy on Alumis, Raises Price Target to $40

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Wells Fargo Maintains Overweight on Alumis, Raises Price Target to $51

Guggenheim Maintains Buy on Alumis, Raises Price Target to $34

HC Wainwright & Co. Downgrades Alumis to Neutral, Maintains Price Target to $25

A Look At Alumis (ALMS) Valuation After Revenue Drop And Narrowed Net Loss

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

Alumis Q1 EPS $(0.74) Beats $(0.77) Estimate, Sales $1.741M Miss $2.767M Estimate

Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans

Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib

Why Is Alumis Stock Falling Monday?

Oppenheimer Maintains Outperform on Alumis, Raises Price Target to $55

HC Wainwright & Co. Maintains Buy on Alumis, Lowers Price Target to $25

Reported Saturday, Alumis' Phase 3 ONWARD Trials Show Envudeucitinib Delivers Robust Skin Clearance And Early Itch Relief In Over 1,700 Plaque Psoriasis Patients, NDA Planned H2 2026

Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout

Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets

Morgan Stanley Maintains Overweight on Alumis, Raises Price Target to $38

Chardan Capital Maintains Buy on Alumis, Raises Price Target to $38